PMA device
Viewpoint Ck System
Refractec, Inc. · Electrosurgical, Radio Frequency, Refractive Correction (MWD, Class III) · First FDA decision Apr 11, 2002, newest Apr 6, 2006Nearsightedness and refractive error
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
PMA pathway
Device trials
0
Naming "Viewpoint Ck"
MAUDE reports
0
Brand "Viewpoint Ck", since 2015
PubMed studies
5
Mentioning "Viewpoint Ck"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Viewpoint Ck System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
- VIEWPOINT CK SYSTEMPMA supplement
P010018-S009 · Decided Apr 6, 2006 · 87 days after receipt · Normal 180 Day Track No User Fee
Device type: Electrosurgical, radio frequency, refractive correction (MWD) · Ophthalmology
- VIEWPOINT CK SYSTEMPMA supplement
P010018-S006 · Decided Jan 15, 2004 · 42 days after receipt · Normal 180 Day Track No User Fee
Device type: Electrosurgical, radio frequency, refractive correction (MWD) · Ophthalmology
- VIEWPOINT CK SYSTEMPMA supplement
P010018-S005 · Decided Mar 16, 2004 · 202 days after receipt · Panel Track
Device type: Electrosurgical, radio frequency, refractive correction (MWD) · Ophthalmology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Viewpoint Ck", any status and sponsor, newest update first.
No registered device study names "Viewpoint Ck".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Viewpoint Ck", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MWD
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Viewpoint Ck"[tiab]. The summary above synthesizes these.
- Outcomes of Conductive Keratoplasty Combined with Corneal Crosslinking in Advanced Ectatic Corneal Disease.
Sinjab MM, Rubinfeld RS, Wagner K, et al. · Clin Ophthalmol · 2021
- Long-term results of conductive keratoplasty for low to moderate hyperopia.
Pallikaris IG, Naoumidi TL, Astyrakakis NI · J Cataract Refract Surg · 2005Research Support, Non-U.S. Gov't
- Two-year follow-up of conductive keratoplasty for the treatment of hyperopic astigmatism.
Naoumidi TL, Kounis GA, Astyrakakis NI, et al. · J Cataract Refract Surg · 2006
- Conductive keratoplasty for low to moderate hyperopia: 1-year results.
Pallikaris lG, Naoumidi TL, Panagopoulou SI, et al. · J Refract Surg · 2003Comparative Study, Research Support, Non-U.S. Gov't
- Femtosecond laser in situ keratomileusis versus conductive keratoplasty to obtain monovision in patients with emmetropic presbyopia.
Ayoubi MG, Leccisotti A, Goodall EA, et al. · J Cataract Refract Surg · 2010Comparative Study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.